167 related articles for article (PubMed ID: 32699671)
1. Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?
Shover CL; Humphreys K
Cureus; 2020 Jun; 12(6):e8671. PubMed ID: 32699671
[TBL] [Abstract][Full Text] [Related]
2. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
3. Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine.
Tran A; Sheikhan NY; Sheikhan T; Nowak DA; Witek TJ
J Cannabis Res; 2021 Dec; 3(1):49. PubMed ID: 34876238
[TBL] [Abstract][Full Text] [Related]
4. Regulatory Status of Cannabidiol in the United States: A Perspective.
Corroon J; Kight R
Cannabis Cannabinoid Res; 2018; 3(1):190-194. PubMed ID: 30283822
[TBL] [Abstract][Full Text] [Related]
5. CBD Retailers in NC Promote CBD Online to Treat Pain Violating FDA Rules About Medical Claims and Offer Low-CBD/High-Price Products.
Amann L; Kruse E; Lazard AJ; Reboussin BA; Wagoner KG; Romero-Sandoval EA
J Pain Res; 2022; 15():3847-3858. PubMed ID: 36514481
[TBL] [Abstract][Full Text] [Related]
6. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
Zenone MA; Snyder J; Crooks V
BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
[TBL] [Abstract][Full Text] [Related]
7. Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products.
Tran T; Kavuluru R
Int J Drug Policy; 2020 Mar; 77():102688. PubMed ID: 32092666
[TBL] [Abstract][Full Text] [Related]
8. Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and Warning Letters From Food and Drug Administration: Content Analysis and Identification.
Turner J; Kantardzic M; Vickers-Smith R; Brown AG
JMIR Infodemiology; 2023; 3():e38390. PubMed ID: 36844029
[TBL] [Abstract][Full Text] [Related]
9. Labeling of Cannabidiol Products: A Public Health Perspective.
Corroon J; MacKay D; Dolphin W
Cannabis Cannabinoid Res; 2020; 5(4):274-278. PubMed ID: 33381640
[No Abstract] [Full Text] [Related]
10. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Stewart KA; Neumann PJ
Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches.
Walker LA; Koturbash I; Kingston R; ElSohly MA; Yates CR; Gurley BJ; Khan I
J Diet Suppl; 2020; 17(5):493-502. PubMed ID: 32543246
[TBL] [Abstract][Full Text] [Related]
12. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
Wang L; Zheng H; Ren X; Sun H
Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
[TBL] [Abstract][Full Text] [Related]
13. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
14. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM
J Clin Pharmacol; 2019 Jul; 59(7):923-934. PubMed ID: 30730563
[TBL] [Abstract][Full Text] [Related]
15. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
Chatterjee S; Patel HK; Sansgiry SS
Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter.
Soleymanpour M; Saderholm S; Kavuluru R
Proceedings (IEEE Int Conf Bioinformatics Biomed); 2021 Dec; 2021():3083-3088. PubMed ID: 35096472
[TBL] [Abstract][Full Text] [Related]
17. Marketing nutrition & health-related benefits of food & beverage products: enforcement, litigation & liability issues.
Roller S; Pippins R
Food Drug Law J; 2010; 65(3):447-69, i. PubMed ID: 24479235
[TBL] [Abstract][Full Text] [Related]
18. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
19. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.
Bramstedt KA
Ther Innov Regul Sci; 2021 Jan; 55(1):239-244. PubMed ID: 33001378
[TBL] [Abstract][Full Text] [Related]
20. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
